244 related articles for article (PubMed ID: 28786848)
1. The biology of prostate cancer metastases: does oligo differ from polymetastatic?
Sonpavde G
Curr Opin Urol; 2017 Nov; 27(6):542-546. PubMed ID: 28786848
[TBL] [Abstract][Full Text] [Related]
2. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract][Full Text] [Related]
3. The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.
Kucharczyk MJ; Gravis G; Niazi T
Eur Urol Focus; 2019 Mar; 5(2):117-118. PubMed ID: 30527643
[TBL] [Abstract][Full Text] [Related]
4. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
Joice GA; Rowe SP; Pienta KJ; Gorin MA
Curr Opin Urol; 2017 Nov; 27(6):533-541. PubMed ID: 28863016
[TBL] [Abstract][Full Text] [Related]
5. Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.
Pasoglou V; Michoux N; Van Damme J; Van Nieuwenhove S; Halut M; Triqueneaux P; Tombal B; Lecouvet FE
World J Urol; 2019 Dec; 37(12):2585-2595. PubMed ID: 30826887
[TBL] [Abstract][Full Text] [Related]
6. Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression.
Sun Z; Zhou S; Tang J; Ye T; Li J; Liu D; Zhou J; Wang J; Rosie Xing H
EBioMedicine; 2018 Nov; 37():47-55. PubMed ID: 30301603
[TBL] [Abstract][Full Text] [Related]
7. Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs.
Uppal A; Ferguson MK; Posner MC; Hellman S; Khodarev NN; Weichselbaum RR
Clin Exp Metastasis; 2014 Aug; 31(6):735-48. PubMed ID: 24968866
[TBL] [Abstract][Full Text] [Related]
8. Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
James ND
Eur Urol Focus; 2019 Mar; 5(2):119-122. PubMed ID: 30803925
[TBL] [Abstract][Full Text] [Related]
9. Oligometastasis: Past, Present, Future.
Gutiontov SI; Pitroda SP; Weichselbaum RR
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):530-538. PubMed ID: 32976785
[TBL] [Abstract][Full Text] [Related]
10. What Is Oligometastatic Prostate Cancer?
Fraser M; Koontz B; Emmenegger U; De Meerleer G; Khoo V; Feng F; Corcoran NM; Hovens CM; Tran PT; Ost P; Boutros PC;
Eur Urol Focus; 2019 Mar; 5(2):159-161. PubMed ID: 30642810
[TBL] [Abstract][Full Text] [Related]
11. Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.
Barzilai O; Versteeg AL; Sahgal A; Rhines LD; Bilsky MH; Sciubba DM; Schuster JM; Weber MH; Pal Varga P; Boriani S; Bettegowda C; Fehlings MG; Yamada Y; Clarke MJ; Arnold PM; Gokaslan ZL; Fisher CG; Laufer I; The Ao Spine Knowledge Forum Tumor
Cancer; 2019 Mar; 125(5):770-778. PubMed ID: 30489634
[TBL] [Abstract][Full Text] [Related]
12. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
Lecouvet FE; Oprea-Lager DE; Liu Y; Ost P; Bidaut L; Collette L; Deroose CM; Goffin K; Herrmann K; Hoekstra OS; Kramer G; Lievens Y; Lopci E; Pasquier D; Petersen LJ; Talbot JN; Zacho H; Tombal B; deSouza NM
Lancet Oncol; 2018 Oct; 19(10):e534-e545. PubMed ID: 30303127
[TBL] [Abstract][Full Text] [Related]
13. [Definitions of oligometastatic disease and new treatment concepts].
Kissel M; Helou J; Thariat J
Bull Cancer; 2018; 105(7-8):696-706. PubMed ID: 29935914
[TBL] [Abstract][Full Text] [Related]
14. Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.
Conde Moreno AJ; Ferrer Albiach C; Muelas Soria R; González Vidal V; García Gómez R; Albert Antequera M
Radiat Oncol; 2014 Dec; 9():258. PubMed ID: 25497220
[TBL] [Abstract][Full Text] [Related]
15. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO).
D'Angelillo RM; Francolini G; Ingrosso G; Ravo V; Triggiani L; Magli A; Mazzeo E; Arcangeli S; Alongi F; Jereczek-Fossa BA; Pergolizzi S; Pappagallo GL; Magrini SM
Crit Rev Oncol Hematol; 2019 Jun; 138():24-28. PubMed ID: 31092381
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression characterizes oligometastasis(es).
Lussier YA; Xing HR; Salama JK; Khodarev NN; Huang Y; Zhang Q; Khan SA; Yang X; Hasselle MD; Darga TE; Malik R; Fan H; Perakis S; Filippo M; Corbin K; Lee Y; Posner MC; Chmura SJ; Hellman S; Weichselbaum RR
PLoS One; 2011; 6(12):e28650. PubMed ID: 22174856
[TBL] [Abstract][Full Text] [Related]
17. Modeling growth kinetics and statistical distribution of oligometastases.
Withers HR; Lee SP
Semin Radiat Oncol; 2006 Apr; 16(2):111-9. PubMed ID: 16564446
[TBL] [Abstract][Full Text] [Related]
18. Oligometastasis and oligo-recurrence: more than a mirage.
Huang F; Wu G; Yang K
Radiat Oncol; 2014 Oct; 9():230. PubMed ID: 25359216
[TBL] [Abstract][Full Text] [Related]
19. [Surgical treatment of local disease in metastatic prostate cancer.].
Gaya JM; Huguet J; Breda A; Palou J
Arch Esp Urol; 2018 Mar; 71(3):288-297. PubMed ID: 29633950
[TBL] [Abstract][Full Text] [Related]
20. [Oligometastatic prostate cancer management].
Kleinclauss F; Thiery-Vuillemin A
Prog Urol; 2019 Jun; 29 Suppl 1():S20-S34. PubMed ID: 31307628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
